About us

Chief Executive Officer at Captor Therapeutics. 30 years’ experience of Biotech senior management in the UK, USA, France, Switzerland, Australia and Poland, leading 12 major license agreements, 6 private investor rounds and 3 IPOs.
Awarded a PhD in biochemistry from Strathclyde University, Glasgow, and CEP diploma from the London Business School. Keen amateur musician and enjoys hiking, sailing, skiing and photography.

Michał Walczak is a Chief Scientific officer, CSO, responsible for R&D and strategy. He obtained a PhD degree from the Swiss Federal Institute of Technology in Zurich , ETH Zurich, and studied at the University of Wroclaw and University of Virginia. He completed his postdoctoral training at the Friedrich Miescher Institute for Biomedical Research in Basel, which is a part of Novartis Institutes for Biomedical Research. Roles played by the member of the Management Board in other companies: Not applicable.

Co-founder and SVP Chemistry of Captor Therapeutics who builds scientific strategy and oversees chemistry efforts. Prior to Captor, served as Global Head at Center for Proteomic Chemistry at Novartis Institutes for Biomedical Research, where he played key roles in multiple successful discovery and development programs, e.g. Afinitor^TM and in-licensing of Gilenya^TM. He studied and received PhD in organic chemistry from EPFL Lausanne. In his free time he enjoys cycling and travelling.

VP of Operations at Captor Therapeutics. Ph.D. in Biochemistry from the University of Wroclaw and Executive MBA from WSB Wroclaw University. Having 15 years of R&D experience, she is responsible for day-to-day operations, overseeing the implementation of optimal processes, standards, and solutions to help the business run smoothly. In her role she has the opportunity for continuous development, and solving daily challenges gives her a lot of satisfaction. As for hobbies, she is an avid traveller and book lover.

Chief Medical Officer (CMO) at Captor Therapeutics responsible for all aspects of clinical development. Obtained a medical degree from Trinity College Dublin in 1989 and has practiced in haemato-oncology for over 30 years in both clinical practice and the pharmaceutical industry. Previous positions include CMO at oncology biotech’s including most recently RedX pharma (U.K.) and Lytix Biopharma Inc (Norway) and oncology drug development roles at Roche and Eli Lilly. Dr. Saunders has acted as an oncology consultant for multiple pharma/biotech companies and holds a diploma in Pharmaceutical Medicine and is a fellow of the Royal College of Physicians, United Kingdom. 

Head of Biology at Captor Therapeutics, where he oversees and coordinates the preclinical development of compounds, including translational studies. He obtained Ph.D. in Molecular and Cellular Biology from the University of Cologne, Germany. With over 30 years of experience in this field, he has held leadership positions and managed projects, teams, and departments in both large pharmaceutical and small biotech companies, primarily in the United States. He has led the development of several novel drug candidates that have entered clinical evaluation, focusing on both oncology and immune diseases. Outside of work, he is passionate about skiing and mountain biking.

Trained medical doctor with a specialization and PhD in Internal Medicine with over twenty years of experience in the clinical development of innovative drugs, both in global pharmaceutical companies, global CRO and biotechnology company. At Captor Therapeutics, he is responsible for the clinical development processes of drug candidates. In his spare time, he is passionate about travel, water sports, cycling and skiing.

As the Vice President of Early Discovery, he oversees cross-functional discovery activities within projects. He holds a Ph.D. from Charles University and completed his post-doctoral training in molecular pharmacology at the University of Glasgow. With over 25 years of experience in the industry, He has progressed from early drug discovery to clinical development while leading cross-functional teams, notably at AstraZeneca R&D and SOTIO Biotech. In his leisure time, he enjoys walking in nature and reading books.

Marta Tomaszewska is VP of People and Culture at Captor Therapeutics. She is a graduate of Wroclaw University of Economics and SWPS University. She has nearly 20 years of professional experience in HR in Polish and foreign companies. She implements HR tools and development projects including recruitment, onboarding, talent management, competence development, and employee engagement building. Supports the Management Board and Managers in making business decisions. Values active recreation, travel, time spent with loved ones, and moments on the mat with yoga.

Chief Financial Officer. Joined Captor Therapeutics after working for almost 20 years on the capital market. Adam previously was the head of the team that managed equity mutual funds at TFI Allianz Polska; worked also, among other companies, for Skarbiec TFI and Credit Suisse Asset Management. Adam graduated from Wrocław University of Economics (financial management) and received PhD from Kozminski University in Warsaw (management and quality sciences). Adam earned several licences and certificates including: the investment adviser licence, the Chartered Financial Analyst charter, and certificates in: management accounting, risk management and managing alternative investments. In his spare time enjoys reading books, playing games (video and board) and gardening.

Chief Business Officer at Captor Therapeutics with more than 30 years’ experience in drug discovery and a unique blend of strategic business acumen and scientific expertise having held both CBO & CSO roles. Experience of leading M&As, licensing, financing, private investment and industry/academic grants and has founded a number of Biotechs. Has led 11 programmes through IND into the clinic. Primary focus in oncology, immune-oncology and immune-inflammation. Currently Expert in Residence for Drug Discovery at the University of Oxford and an Advisory Board member for three European Biotechs. Holds a D.Phil in Biochemistry from The University of Oxford and an MBA from Oxford Brookes University.